Evidence map›Paper›PMID 32446836›Full record

ArticleVaccine2020

Effectiveness of 'catch-up' human papillomavirus vaccination to prevent cervical neoplasia in immunosuppressed and non-immunosuppressed women.

Michael J Silverberg, Wendy A Leyden, Jennifer O Lam, Chun R Chao, Steven E Gregorich, Megan J Huchko, Shalini Kulasingam, Miriam Kuppermann, Karen K Smith-McCune, George F Sawaya

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Michael J SilverbergDivision of Research, Kaiser Permanente Northern California, Oakland, CA, USA. Electronic address: Michael.J.Silverberg@kp.org.
Wendy A LeydenDivision of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
Jennifer O LamDivision of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
Chun R ChaoDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Steven E GregorichDepartment of Medicine, University of California at San Francisco, San Francisco, CA, USA.
Megan J HuchkoDepartment of Obstetrics, Gynecology & Reproductive Sciences, University of California at San Francisco, San Francisco, CA, USA; Department of Obstetrics and Gynecology, Global Health Institute, Duke University, Durham, NC, USA.
Shalini KulasingamDivision of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA.
Miriam KuppermannDepartment of Obstetrics, Gynecology & Reproductive Sciences, University of California at San Francisco, San Francisco, CA, USA; Department of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, CA, USA.
Karen K Smith-McCuneDepartment of Obstetrics, Gynecology & Reproductive Sciences, University of California at San Francisco, San Francisco, CA, USA.
George F SawayaDepartment of Obstetrics, Gynecology & Reproductive Sciences, University of California at San Francisco, San Francisco, CA, USA; Department of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, CA, USA.
Kaiser Permanente · USUniversity of California, San Francisco · USDuke University · USUniversity of Minnesota · US

Funding

Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 2001 to 2026
$57.4M
Using comparative effectiveness analyses to optimize cervical cancer screeningR01CA169093 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SAWAYA, GEORGE F · 2013 to 2016
$2.2M
NCI NIH HHS R01 CA169093NIMH NIH HHS P30 MH062246
6 · The paper itself

Abstract

It is unknown whether the HPV vaccine is effective in immunocompromised women during catch-up ages. We performed a case-control study of 4,357 women with incident CIN2+ (cases) and 5:1 age-matched, incidence-density selected controls (N = 21,773) enrolled in an integrated health care system from 2006 to 2014. Vaccine effectiveness was estimated from multivariable conditional logistic regression models, with results stratified by immunosuppression history, defined as prior HIV infection, solid organ transplant history, or recently prescribed immunosuppressive medications. HPV vaccination resulted in a 19% reduction in CIN2+ rates for women without an immunosuppression history but a nonsignificant 4% reduction for women with an immunosuppression history. Further research is needed to evaluate whether catch-up HPV vaccine effectiveness varies by immunosuppression status, especially given the recent approval of the HPV vaccine for adults up to 45 years of age.

Indexed as

AlphapapillomavirusHIV InfectionsPapillomavirus InfectionsPapillomavirus VaccinesUterine Cervical NeoplasmsAdultCase-Control StudiesFemaleHumansVaccinationPapillomavirus VaccinesHIVHuman papillomavirusImmunosuppressionVaccination

Identifiers

PMID32446836
PMCPMC7272293
OpenAlexW3027601268

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.